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Chronic respiratory diseases affect a large number of subjects in Italy and are
characterized by high socio-health costs. The aim of the Social Impact of Respiratory
Integrated Outcomes (SIRIO) study was to measure the health resources consumption and
costs generated in 1 year by a population of patients with chronic obstructive pulmonary
disease (COPD) in a real-life setting. This bottom-up, observational, prospective,
multicentric study was based on the collection of demographic, clinical, diagnostic,
therapeutic and outcome data from COPD patients who reported spontaneously to
pneumological centers participating in the study, the corresponding economic outcomes
being assessed at baseline and after a 1-year survey. A total of 748 COPD patients were
enrolled, of whom 561 [408m, mean age 70.3 years (SD 9.2)] were defined as eligible by
the Steering Committee. At the baseline visit, the severity of COPD (graded according to
GOLD 2001 guidelines) was 24.2% mild COPD, 53.7% moderate and 16.8% severe. In the 12
months prior to enrollment, 63.8% visited a general practitioner (GP); 76.8% also consulted
a national health service (NHS) specialist; 22.3% utilized Emergency Care and 33% were
admitted to hospital, with a total of 5703 work days lost. At the end of the 1-year survey,
the severity of COPD changed as follows: 27.5% mild COPD, 47.4% moderate and 19.4%
severe. Requirement of health services dropped significantly: 57.4% visited the GP; 58.3%
consulted an NHS specialist; 12.5% used Emergency Care and 18.4% were hospitalized.
Compared to baseline, the mean total cost per patient decreased by 21.7% (po0.002). InElsevier Ltd. All rights reserved.
o, Multidisciplinary and Outpatient Rehabilitation Clinic, 28021 Borgomanero, Novara, Italy.
edico.it (C.F. Donner).
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Costs of COPD in Italy 93conclusion, a significant reduction in the use of health resources and thus of COPD-related
costs (both direct and indirect costs) was observed during the study, likely due to a more
appropriate care and management of COPD patients.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is the chronic
respiratory disorder that currently represents the most
significant health problem at international level: its epide-
miological, clinical, social and socio-economic impact is
progressively rising and there are no signs of any change to
this trend. Moreover, COPD represents an enormous health
problem for the community, affecting patients and their
families, the employment sector, the institutional network
and hence society as a whole dramatically.1–6
Cost of illness (COI) analysis, carried out by means of the
measurement and estimation of the resources consumption
used in disease management, is a useful methodological tool
that broadens the criteria for evaluating the effects of a
given disease since it provides information about the
economic (as well as clinical) effects that the disease has
on the entire ‘‘health system’’.
In face of the ever growing need to reconcile the limited
available economic resources with an increasing demand for
well-being from the general population, already for a
number of years the health services of industrialized
countries have been devoting attention to the costs
generated by healthcare in their own territories. Data that
permit an estimate of such costs should ideally be produced
in a ‘‘real’’ context, if they are to reflect faithfully what is
happening in everyday life: only in this way can they be fully
credible and of use to the institutions for future planning.
From this arises the importance of observational studies
on health outcomes, aimed not only at reducing costs but
also at optimizing management and ensuring a more
rationalized use of resources.
Chronic respiratory diseases, in particular, concern a large
number of subjects and generate important health and
social costs. The global impact of these diseases, in
particular COPD, is the subject of an increasing number of
pharmacoeconomic studies published in the literature over
the last few years.7–17 Although these studies were based on
different experimental designs, they nevertheless confirm
the elevated and growing impact of COPD in all countries,
from the perspective both of the patient and family, and
that of society as a whole. The findings that emerge
highlight moreover that the attitude towards COPD manage-
ment is still largely inadequate.7–9,13,14,17
To provide an updated contribution in this field with
regard to Italy, the Social Impact of Respiratory Integrated
Outcomes (SIRIO) study was designed as a global outcome
study to produce data regarding the socio-economic impact
of the major respiratory diseases (bronchial asthma, COPD,
community acquired pneumonia—CAP). In this article, we
report exclusively data concerning COPD.
Due to the strategic value of the initiative—something of
a novelty in our country—SIRIO was promoted by UIP
(Unione Italiana per la Pneumologia–Italian Union forPneumology) and endorsed by the following scientific
societies: AIPO—Associazione Italiana Pneumologi Ospeda-
lieri (Italian Association of Hospital Pneumologists) and
SIMeR—Societa` Italiana Medicina Respiratoria (Italian So-
ciety of Respiratory Medicine).
Materials and methods
The SIRIO/COPD study consisted in the creation of an on-line
pharmacoeconomic network on COPD in Italy. The study was
not designed to evaluate pharmaceutical drugs, nor ther-
apeutic strategies, nor diagnostic procedures: its aim was
purely to provide an updated estimate of the economic cost
of COPD in an Italian population affected by this disease.
The choice of a prospective design allowed a greater
precision in describing the different items for expenditure,
the quality, specificity and speed of data calculation being
optimized by a dedicated software system for the collection
and on-line analysis of data.
Design and procedures
This bottom-up, observational, prospective, multicentric
study was based on the collection of demographic, clinical,
diagnostic, therapeutic and outcome data of COPD patients
who spontaneously requested a pneumological consultation.
Patients’ inclusion in the study did not imply any procedure,
risk or advantage other than those of routine clinical
practice. Patients were enrolled in the study if they fulfilled
the following inclusion criteria: males or females of adult
age (18 years) with a diagnosis of COPD according to the
GOLD 2001 guidelines18 in stable phase or symptomatic, who
reported spontaneously to the specialist center as a first-
time patient, as a previous patient coming for a scheduled
check, or as a previous patient coming with symptoms of
COPD exacerbation. The only exclusion criterion was that
patients should not be enrolled in any clinical study. All
subjects gave informed consent to participate in the study
and allowed the use of their personal data for research
purposes.
The study envisaged a minimum of two visits, i.e. one at
baseline and the other after 1271 months; if necessary,
further visits were possible during the 1-year survey. At
baseline, demographics (age, sex, marital status and
employment status), clinical data (symptoms; disease
duration, disease severity, and frequency of exacerbations,
including the presence of comorbidities), diagnostic infor-
mation (type and number of specialist/non-specialist ex-
aminations performed to assess COPD in the 12 months prior
to enrollment), some outcomes (GP and specialist visits,
recourse to Emergency Care, hospital admissions, Day
Hospital, work days off in the 12 months prior to
enrollment), and information on therapeutic consumption
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who spontaneously referred to the specialist centers had
already received their diagnosis of COPD. Nevertheless,
diagnosis was confirmed in the recruited patients by
collecting anamnestic data, clinical information, and lung
function data. In many cases, GPs’ files were also consulted
to clarify particular situations, e.g. concerning the number
of admissions or number of diagnostic tests carried out in
the 12 months prior to enrollment.
As SIRIO study was an observational survey in real life,
physicians had the opportunity to prescribe the treatment
they considered as most suitable for the patient’s condi-
tions; hence, no pre-set treatment was indicated to the
physicians taking part in the study, nor were any manage-
ment recommendations given. During the baseline visit
patients were given the self-administered health status
questionnaire EQ-5D (Euro-Qol, Quality of Life in Europe, 5
Dimensions) to fill in19 together with a visual analogic scale
(VAS) in order to assess their health status.
The end-study visit was scheduled to take place at the
end of the follow-up period, i.e. at 1271 months following
the patient’s recruitment. If an unscheduled visit to the
specialistic center occurred within this time-frame, it could
be used as the end-study visit. Other visits that occurred
close to the end-date of the study, but outside the period of
71 month allowed, were not considered as end-study visits,
and the patient was further recalled for a specific end-study
visit, within the time interval established by the protocol. If
the patient could not be contacted, or skipped, or had died
in the interim, the specialist registered the information on
the data collection card.
At the end-study visit, the same data collected during the
baseline visit were updated. As this visit was part of the
protocol, it was not considered in terms of resource
consumption. On the contrary, if a patient made an
unscheduled visit to the center for any healthcare inter-
vention related to the COPD conditions, and if this occurred
within the time-frame of the end-of-study visit (1271
months since the recruitment), that visit was calculated as
additional healthcare consumption, since it was not induced
by the protocol but spontaneously generated by an
uncontrolled clinical change.Data collection
Study data were collected through a dedicated software
that encrypted patients’ names to guarantee anonymity;
data were sent via e-mail to the coordinating center which
housed the central database.
The questionnaire EQ-5D was given to patients in paper
form; all questionnaires were then sent by mail to the
database center.Study dimension
To ensure that data were representative of the whole of
Italy Pneumological Centers were selected by the two
endorsing Scientific Societies according to strict geographi-
cal criteria for distribution; moreover, the modes of data
collection envisaged by the protocol made participation inthe study possible only for centers equipped with suitable
computer systems.
In the global design phase of SIRIO, we hypothesized a
variability of cost range of between 150% and 200% for the
diseases considered, and we therefore established that a
statistical sample totaling between 1000 and 1500 patients
would allow an estimate with a 10% margin of error (with
95% confidence interval). Moreover, considering a drop-out
percentage at follow-up of around 10–15%, each center
would have to recruit a total of approximately 50 patients,
variously distributed between asthma, COPD and CAP.
In each center, patients were enrolled consecutively,
according to the order in which they presented to the
pneumologist for consultation.
Data analysis
In order to analyze all data in the whole COPD sample,
descriptive statistics were used.
Descriptive statistics were used to analyze the demo-
graphic, clinical and treatment characteristics of the total
study population and of the subgroup of patients affected by
COPD.
Statistical comparisons were calculated by means of non-
parametrical tests (Welch test) in order to compare
variations in the most relevant outcomes versus baseline
values (e.g. mean costs for each level of asthma severity;
mean total cost of illness), and a po0.05 was accepted as
the minimum level for statistical significancy.
Health costs
The healthcare interventions (e.g. visits, diagnostic tests,
hospital admissions, etc.) had been valued and correspond-
ing real costs attributed.20–23
The following categories of costs were considered:
Direct
These are the costs effectively generated by the respiratory
disease and/or paid for by the patient. They include direct
health costs, i.e. the monetary value of the resources used
in the diagnosis and treatment (therapies, hospitalization,
etc.) and in general constitute an economic burden borne
chiefly by the NHS.
Both treatment for COPD and that for comorbidities were
calculated as direct costs. Concomitant pharmacological
treatment was defined as ‘‘any treatment needed to treat
any disease different from COPD or comorbidity which the
patient is suffering from’’.
Furthermore, the direct non-medical costs of different
origin (e.g. transfers of patient and caregivers for examina-
tions and/or hospitalization, home care, etc.) were calcu-
lated using average unitary costs of different types,
according to the case (transport tariffs, tariffs for paid
caregivers, etc.).
Indirect
These are costs corresponding to the loss of productivity
occurring as a result of a patient’s inability to work (or
death) on account of the disease. The economic burden of
indirect costs is borne essentially by the society.
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Table 1 Characteristics of study population.
No. (%)
Total 561
Mean ageyears (S.D.) 70.3 (9.2)
Sex
Males 408 (73.0)
Females 153 (27.0)
Geographic distribution
North 174 (31.0)
Centre 156 (28.0)
South 231 (41.0)
Occupational status
Retired 431 (76.8)
Housewife 51 (9.1)
Full-time employee 43 (7.7)
Self-employed 28 (5.0)
Other 8 (1.4)
Smoking habit
Non smoker 86 (15.2)
Smoker 60 (11.0)
Ex-smoker 265 (47.2)
N/A 150 (26.6)
Respiratory therapy
Yes 541 (97.0)
No 20 (3.0)
Costs of COPD in Italy 95To evaluate the indirect costs, we referred to the activity
carried out by the patient, considering the average daily
wage that such activity implies.
Intangible
These are costs not convertible in monetary terms, in that
they relate specifically to the distress and suffering caused
by the disease. Measurement of the patient’s self-perceived
health status is performed by means of quantitative scales.
The perception of a poorer health status due to the disease,
compared to a conventional value indicating full health, was
considered as a proxy of the intangible costs.
Health status
Measurement of health status was performed by means of
the questionnaire EQ-5D, in the official Italian version,19
which is a simple generic instrument of general applicability
to diseases and treatments. Patients identify their own
health status indicating on the first page of the question-
naire which level of attitude (of the three given) best
corresponds to their situation for each of the five dimen-
sions: (1) movement capacity, (2) personal care, (3) habitual
activities, (4) pain or irritation, (5) anxiety and depression.
Each dimension has three response levels, giving thus 243
possible health statuses. The information gathered is
synthesized by an algorithm into a score ranging from 0 to 1.
On the second page of the questionnaire patients are
required to indicate on a VAS their currently perceived
health status: the linear VAS grade was from 0 (worst health
status imaginable) to 100 (best health status imaginable).
As the instrument’s output is a single numerical value that
expresses the health-related quality of life, it can be used in
cost-utility analyses. Generally, it takes just a few minutes
to complete the EQ-5D.
Ethical issues
The study was approved by the Ethics Committee of the
Coordinating Center which notified all participating centers.
Results
Of the 37 Pneumology Centers distributed throughout Italy
initially involved in the study, 32 of them enrolled subjects
with COPD effectively. The five centers which did not recruit
any subjects had severe bureaucratic delays with their local
ethical committees and missed the deadline for entering the
study: there was no particular geographic bias in the
distribution of these centers.
Demographic, clinical and diagnostic data
In the period November 2001–December 2003, 748 COPD
patients were enrolled, but only 561 of them (408 males;
mean age 70.3 years79.2 SD) fully completed the 1-year
survey and thus were considered eligible for analysis (those
patients who spontaneously interrupted their participation,
were never seen, or whose forms were incompletely filled in
were considered ineligible). In the course of the survey atotal of 11 patients died: all were severe COPD patients (in
stage 3 category which represented 16.8% of the overall
group). No deaths were observed in the other groups. The
geographical distribution of the 561 patients who underwent
analysis is reported in Table 1. The most represented
category was that of retired, while the least represented
was that of full-time employees; current and ex-smokers
were the majority of the patient sample (Table 1).
The average distance traveled by patients to reach the
specialist center was 27.4 km, with a maximum of 122.9 km
and a minimum of 4.9 km in two centers, respectively, in
south and central Italy.
In the vast majority of patients (91.1%), COPD had been
already diagnosed, the mean duration of COPD being on
average 13.3 years. At enrollment, mean lung function
(FEV1) in the clusters of patients with different COPD
severity according to the GOLD 2001 guidelines was as
follows: level 0, 88.1%79.8 (mean FEV1% pred.7SD); level
1, 86.0%77.9; level 2, 54.2%710.1; level 3, 22.3%77.6
(Figure 1A).
At the time of enrollment, almost all patients (94.7%)
with a previous diagnosis of COPD had already performed at
least one spirometry test; 1.8 years was the average time
lapsed since the last spirometry. In patients with a first-time
diagnosis of COPD, spirometry had already been performed
in 64% of subjects.
At least one comorbidity was present in 67.7% of patients,
and their frequency is reported in Figure 2: cardiovacular
comorbidities were the most represented.
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Figure 1 (A and B) Distribution of COPD patients according to
their clinical severity (GOLD 2001): (A) baseline; (B) follow-up.
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carried out a total of 2385 diagnostic tests. A list of those
most frequently performed (41%) is reported in Figure 3. Of
note, the total value spent for diagnostic procedures was
quite low (6% of total cost).Outcome data
The absolute number and corresponding percentage of
subjects who visited the GP, consulted an NHS specialist,
utilized Emergency Care, or who were hospitalized at least
once during the 12 months prior to enrollment are reported
in Table 2A, together with the overall number of work days
lost (5703).
Changes in COPD severity as assessed at the end of the
survey are reported in Figure 1B. Changes in all outcomes
monitored during the study (e.g. number of visits, number ofhospitalizations, etc.) are reported in Table 2B analytically,
together with the corresponding number of work days off.
All these figures dropped dramatically at the end of the
survey.Evaluation of costs
The mean total direct costs per patient are reported in
Table 3; in general, total cost of illness dropped significantly
at the end of the 1-year survey (po0.002). Mean total cost
in females was significantly higher than that calculated in
males (h2191.7373098.66 versus h2923.1674057.60 SD,
respectively; p ¼ 0.022).
Of note, in spite of the substantial increase in pharma-
ceutical costs, there was a significant drop in all other direct
costs: in particular, there was a substantial reduction in
costs due to hospitalizations and Emergency Care. Indirect
mean costs also decreased significantly during the 12-month
survey (Table 3).
Total mean cost proved proportional to the severity of
COPD, varying from h1314.947 1830.61 SD for mild disease
to h5451.6675312.67 SD for more severe COPD (Figure 4A
and B) (po0.01). Moreover, the statistical comparisons
between costs calculated for the corresponding COPD stages
before and after the survey were: stage 0, p ¼ ns; stage 1,
p ¼ 0.05; stage 2, p ¼ 0.004; p ¼ 0.056, respectively. In
other words, only stages 2 and 3 showed that they can in real
life be influenced by a more strict control of COPD patients.
In total, the mean cost per patient decreased by h590.79 at
the end of the survey (po0.001) (Table 3).Treatment data
Both at baseline and at the end of the study, 97% of patients
were pharmacologically treated for their COPD, thus
supporting the hypothesis that the clear improvement in
ARTICLE IN PRESS
Table 2 A and B—visits and/or hospital admissions and/or Emergency Care use by patients: (A) baseline; (B) follow-up.
Visits/admissions A (n ¼ 561) B (n ¼ 561)
Total, n n No. of patients % Patients Total, n n No. of patients % Patients
Visits to GP 2541 358 63.8 1361 322 57.4
Visits to NHS specialist 1335 431 76.8 812 327 58.3
Visits to private specialist 123 56 10.0 108 51 9.1
Access to Emergency Care 207 125 22.3 104 70 12.5
Hospital admission 268 184 33.0 148 103 18.4
Day Hospital 199 32 5.7 158 30 5.3
Total work days off 5703 5212
Table 3 Direct, indirect and total mean costs per patient.
Parameters Baseline Follow-up
Mean cost per patient (n ¼ 561) Mean cost per patient (n ¼ 561)
Value in h % Value in h %
Principal pharmacological therapy 347.23 12.7 663.78 31.1
Concomitant pharmacological therapy 186.82 6.9 256.44 12.0
Hospital admissions 1519.67 55.8 823.12 38.6
Day Hospital 88.68 3.3 70.41 3.3
Access to Emergency Care 7.62 0.3 3.83 0.2
Visits to GP and specialist 150.59 5.5 93.99 4.4
Examinations 162.68 6.0 124.66 5.8
Verifications of side effects 0.70 0.0 0.12 0.0
Environmental preventive therapy and home help 3.07 0.1 2.35 0.1
Alternative therapyy 39.77 1.5 5.88 0.3
Total direct costs 2506.84 92.0 2044.58 95.9
Work days lost 216.84 8.0 88.31 4.1
Total indirect costs 216.84 8.0 88.31 4.1
Total costs 2723.6873831.24 100 2132.8972776.30z 100
Spirometry, blood gases analysis, allergic skin tests, chest X-ray, sputum test, strength test, Walking test, bronchial provocation
test, bronchodilatation test, bronchoscopy, etc.
yThermal cures, homeopathy, etc.
zpo0.002.
Costs of COPD in Italy 97economic outcomes is not due to a higher percentage of
treated patients at the end of the 12-year survey (Table 1).
In the 12 months prior to enrollment, respiratory drugs
accounted for 12.7% of the total cost of the disease, while
those prescribed for the management of concomitant
diseases represented 6.9%. Costs related to alternative
therapies (homeopathy, etc.), environmental preventive
treatments, and to the performance of medical procedures
secondary to negative side effects consequent upon the
assumption of therapeutic drugs (both for basic and
concomitant therapy) were completely marginal (Table 3).
At the end of follow-up, a notable increase was observed in
pharmaceutical costs (31.1% in those for respiratory drugs
and 12.0% in those used to treat comorbidities). This
occurred without any increase in the percentage of subjects
treated for COPD, which was unchanged.However, as mentioned above, the increase in costs of
basic therapy was offset by a marked, systematic decrease
in all other direct costs as well as in the indirect costs
induced by the disease.
The total mean cost of COPD showed some variations
according to the geographical zone of patient recruitment.
Even though statistically not significant (p ¼ ns), the cost in
the central Italian regions was lower than the mean national
cost, while in the southern regions it was higher (Figure 5).
This gradient persisted also when subjects were subdivided
according to clinical severity. Moreover, in the 12 months
prior to enrollment, northern regions produced the lowest
mean indirect costs in the same period. At the end of the
survey, a significant reduction of both direct and indirect
costs was in any case observed in all the three macro-regions
considered in the study.
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The awakening of international focus on COPD dates back to
just a few years ago, in response to its ever growing
prevalence and increasing incidence. The concern about
COPD is in fact of more recent date than that about
bronchial asthma, which first began to cause alarm about 15
years ago. It is in fact just a few years ago that the study was
published which forecast that, in 2020, COPD would
represent the third-ranking cause of mortality in the world.1
Awareness about the global problem of COPD was
subsequently promoted also by the European Respiratory
Society which, in 2003, published the first European report
on respiratory diseases by proposing its importance as a
health and social issue to all European citizens and invoking
the attention of political leaders.24,25 Even if the impor-
tance of COPD still does not appear to be fully grasped by all
parts of the social and institutional infrastructure, the
European report in any case helped draw attention to the
elevated impact of COPD as a disease in the community. The
report moreover evidenced the distribution of COPD in the
different European countries, with up-to-date data on the
costs, risk factors, diagnostic techniques and therapeutic
options (pharmacological and non-pharmacological).
Generally, the impact of COPD is high in all countries,
particularly in the more industrialized ones.8,13–16,25 Never-
theless, as for asthma, also for COPD the global impact has
been demonstrated to be independent of the specific health
and welfare models adopted in the each single country.
In USA, the country that first undertook to analyze the
economic impact of the disease, the total cost of COPD was
recently estimated at $24 billion, more than 60% of which
was due to direct costs, 18% to loss of earnings due to early
death, and 20% to morbidity.25
In Italy, in 1997, COPD represented the fifth cause of
hospitalization for non-surgical causes, determining more
than 1 million days of hospital stay (data ISTAT). In 1999,
ISTAT also documented that 2.6 million Italian citizens were
affected by COPD, with a mortality of approximately 18,500
individuals, which represents more than 50% of all causes of
death for respiratory causes. From more recent data, it0
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stage 3, po0.056.appears that 6% of individuals aged between 46 and 55
years, and 11% of individuals over 55 years of age, are
affected by COPD in our country.24
Unfortunately, not a lot of data are available in Italy
concerning the prevalence of different classes of COPD
severity. In particular, the only data available derive from
epidemiologic studies carried out by means of questionnaire
investigations. Even though the present study was carried
out in a different setting (the target was patients recruited
in hospital outpatient clinics, and COPD prevalence was
24.2% mild, 53.7% moderate and 16.8% severe), correspond-
ing results were found in two other previous Italian
studies.7,27 In these studies, mild COPD was around 30%,
while moderate around 55%, and severe around 12%.
SIRIO results are in good agreement also with the most
recent data on distribution of different stages for COPD
severity, which are based on national epidemiological
data.25,27 Also in Italy COPD has been demonstrated to have
an extremely significant socio-economic impact. In our
study, the mean annual cost per patient was h2133,
corresponding to a 20% increase with respect to the cost
calculated 5 years previously in a similar, but not identical
study (a bottom-up pilot study based on a national
population of more than 5 million inhabitants based on
telephone interviews).26 Significant differences were regis-
tered according to the clinical severity of the disease, the
cost varying from h1500.8 for the milder forms (65% of
cases) to h3001.1 for moderate forms (30% of cases) to
h3911.7 for severe COPD (5% of cases).7
The above-mentioned nation-wide survey based on tele-
phone interview, showed that in Italy there is still a long
road to go before we reach an acceptable management
control of COPD. In this study, in fact, 28% of the subjects
interviewed declared to be little or not at all clinically
controlled by their current therapy and more than 60% of
these subjects reported they had had to consult their GP at
least three times in the last 12 months on account of COPD:
added to this were, on average, two more specialist
consultations effectuated in the same period. Moreover,
19% of the visits performed resulted unscheduled and were
related to a sudden worsening of the disease. Finally, in the0
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patient (h).
Table 4 Health questionnaire EQ-5D and VAS scores in
all patients and in patients subdivided by age category.
No. of
patients
Score
Mean S.D. Minimum Maximum
EQ-5D 414 0.683 0.255 0.429 1.000
19–64
years
107 0.693 0.275 0.358 1.000
465
years
307 0.680 0.249 0.429 1.000
VAS 414 0.588 0.183 0.000 1.000
19–64
years
107 0.623 0.203 0.000 0.960
X65
years
307 0.576 0.175 0.000 1.000
Normal references for Euroqual User Guide values:
total ¼ 0.856; subject o65 years ¼ 0.885; subject 465
years ¼ 0.740.
Costs of COPD in Italy 99last 12 months, 11% of the subjects had been admitted to
hospital, and 6% had passed through an emergency or
intensive care unit. Only 35% of subjects had been regularly
prescribed respiratory drugs, and in more than 50% of these
the treatment had consisted in the sole repeated assump-
tion of antibiotics, in some cases up to 20 cycles in the 12
months. In the same study, the hospitalization phenomenon
had been found to account for 3/4 of the total cost. Once
again, the cost varied as a function of clinical severity,
reaching an approximate cost of h7000 per patient per year
in the more severe stages of COPD. Furthermore, the mean
costs were far higher in males (+160%), in subjects with
comorbidities (+82%), and in those not enrolled in specific
educational programs (+42%). In any case, the incidence of
costs related to diagnostic procedures and therapeutic
treatment resulted very low (globally only 17%).26
It is known that, in the course of COPD, the most frequent
cause of hospitalization, and thus the most significant item
of cost, is the event of exacerbation.13,14,17,28–30 Patients
can experience up to three or four exacerbations per year,
of varying degrees of severity. The causes of exacerbation
are multiple, and include late diagnosis of COPD, a
healthcare organization still based on hospitalization, and
inappropriate treatment and management. In this regard, it
should be noted that treatment failure of an exacerbation
(due to underestimation and/or inappropriateness) leads, in
economic terms, to a far higher consumption of resources
than that required for the exacerbation itself.13,14,30
Generally speaking, in order to provide information that is
reliable and able to effectively influence the strategic
decisions aimed at controlling an expanding disease like
COPD, epidemiological and pharmacoeconomic studies need
to be conducted more frequently, so as to render more
stable the available data and, at the same time, monitor
eventual management or behavioral constraints on the state
of control of the disease.
Actually, the SIRIO study seems to fit well this bill, aimed
as it is to produce up-to-date data on the health resources
consumption and costs generated by COPD in Italy. The study
design (observational, prospective, multicentric) was cho-
sen precisely to allow a comparison between current data
and historical data previously collected through the same
bottom-up methodology.In our study, COPD was confirmed in our country to be still
most prevalent in males, in smokers (ex or current), and in
the older age groups, i.e. in those subjects who represent
the weakest and the least active individuals in socio-
economic terms, but without any significant regional
differences.
In our study group, the incidence of clinically important
concomitant diseases emerged as very significant. Heart
diseases (in particular hypertensive and ischemic heart
disease), dysmetabolic diseases (diabetes, dyslipidemia),
gastric diseases and cancer resulted the most prevalent
comorbidities.
Actually, COPD patients appear to be a particularly fragile
population in which the effects of disability induced by
precarious clinical conditions involving diverse organs and
systems interact, in an additive and/or synergic way, with
those of the basic disability determined by COPD. It however
should be emphasized that in the representative sample
COPD resulted of moderate severity in more than 50% of
cases, but that, on the other hand, severe COPD showed an
incidence of 16% in the recruited subjects. This clinical
impact appears further confirmed by the poor quality of life
that characterized, on the basis of data collected from both
questionnaires used (VAS and EQ-5D), our COPD subjects:
this finding was independent of the age class of single
subjects (Table 4).3
From the above evidence one cannot but deduce that
COPD still has a very high socio-economic impact in Italy,
which society will have to face in the near future if it wants
to avoid the health system getting ‘‘out of control’’.
The consumption of resources and health goods was found
to be consistent with a frequent recourse to GP and
specialist consultations, hospitalization, and use of urgen-
cy–emergency facilities. In other terms, at a distance of only
a few years from the two previous Italian studies on
COPD,7,26 data of the SIRIO study document a further, not
negligible increase in the impact of COPD and indicate that
the disease control is still a long way from being adequate at
territorial level.
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thus principally the state of local management), the total
annual mean cost of COPD was more than h2700 per patient:
in fact a mean cost of approximately 22% more than what
was documented only a few years ago in a comparable
bottom-up study. This preoccupying development in costs
was confirmed also when the different levels of clinical
severity of COPD were considered, in particular for the more
severe clinical conditions.
What once again emerges from the present findings is the
dramatic incidence of direct costs, mainly due to hospita-
lizations, which is in contrast to the modest incidence of
treatment costs and a negligible role of diagnostic costs.
As in several other countries, also in Italy the present
diagnostic approach to COPD is still far from the GOLD
standard. Spirometry still is used only in the vast minority of
patients (20–25% of cases) both for diagnostic and for
monitoring purposes. Furthermore, the therapeutic ap-
proach is mainly based on short-acting beta-agonists as
required; moreover, LABA (alone or in combination with ICS)
and/or anticholinergics are also used but off label in the
majority of cases (particularly in mild-to-moderate COPD),
where the correspondance with COPD severity is very poor.
The aim of SIRIO was also to estimate the resources
expenditure over the follow-up period. At the end of the
study, we observed a significant, consistent decrease in the
total mean cost (17%), correlated in particular to an
equally significant reduction of the direct mean costs
(18.4%). As the number of subjects in treatment for COPD
remained absolutely unmodified (97% before and after
follow-up), this management finding is probably attributable
to the sole fact of more appropriate therapeutic interven-
tions during the period of follow-up (ICS, LABA, etc.). On the
other hand, corresponding to a significant increase in the
cost for pharmaceutical drugs (both those of principal
therapy and those for concomitant diseases) there was in
fact a net decrease in visits made to the GP and specialist,
use of emergency structures, hospitalization, work absen-
teeism, and use of alternative therapies. Even if indirectly,
the picture that clearly emerges at the end of the survey is
of an improved general respiratory health status of the
COPD patients recruited, thus confirming the partial treat-
ability of COPD and the possibility to minimize related costs.
These positive results in terms of direct and indirect
savings remained equally significant when COPD patients
were divided by the level of their clinical severity and by
geographical zone of enrollment.
Generally, this confirms once again that an attentive and
appropriate use of the therapeutic resources currently
available represents the key point on which to base the
management of COPD (a disease in itself difficult to
control), both in terms of efficacy and efficiency. It should
not come as a surprise that the findings emerging from SIRIO
highlight the fact that outcome optimization and reduction
of costs are obtainable simply through a more appropriate
utilization of the available resources. This finding is
confirmed by a recent study carried out in subjects with
severe and very severe COPD which showed the possibility to
optimize clinical outcomes maintaining the same level of
health resources and costs.30
However, it still emerged as critical the situation of COPD
patients who come too late to the attention of the medicalspecialist and whose disease continues to be underestimated
both from a diagnostic (there is still inadequate recourse to
suitable and appropriate investigations) and therapeutic
point of view.
Globally, the findings of the SIRIO study show that today,
and in the near future, to implement the best strategies of
intervention it is fundamental to have periodic recourse to
analyses on the impact of the most frequent chronic/
persistent respiratory diseases, in particular COPD. If
effective and credible study models are used, these
evaluations based on the estimate of resources consumption
required for disease management will increasingly represent
an indispensable decisional tool that can guide decision
makers in future health policies, both at local and national
level. Vice versa, if such information is not available, this
will inevitably end by negatively affecting the quantity and
quality of the efforts to manage the disease, as well as the
sensitivity and specificity of the markers used to monitor
outcomes. It is equally inevitable that, in the final analysis,
what will suffer most will be the effectiveness and
tempestivity of the healthcare planning to cope with this
growing and challenging respiratory disease.
The message for the Italian healthcare system is that
COPD continues to rise and that it is causing an ever
increasing economic burden for society and the patient. A
second message is that more effective territorial strategies
for controlling COPD should be implemented in the very near
future in order to avoid an uncontrolled explosion of health
costs in the most ageing country in Europe. Data in real life
point to this dangerous drift in healthcare costs.
In fact, only by following management programs inspired
from the knowledge and objective documentation of the
events driving COPD management at local level is it possible
to obtain reliable data, on the basis of which decision-
makers will be able to plan more useful, incisive and
realistic interventions for the benefit of the whole commu-
nity.Conflict of interest
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